438564-36-4

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
5-nitro-2-(trifluoroMethyl)pyridin-4-aMine is utilized as an intermediate in the synthesis of pharmaceuticals and agrochemicals due to its versatile chemical structure and reactivity. Its presence in the synthesis process contributes to the development of new drugs and pesticides with improved efficacy and selectivity.
Used in Dye and Pigment Production:
In the dye and pigment industry, 5-nitro-2-(trifluoroMethyl)pyridin-4-aMine is employed as a key component in the production of various dyes and pigments. Its unique molecular structure allows for the creation of a wide range of colors and properties, enhancing the performance and versatility of these products.
Used in Medicinal Chemistry for Antimicrobial and Antiparasitic Applications:
5-nitro-2-(trifluoroMethyl)pyridin-4-aMine is recognized for its antimicrobial and antiparasitic properties, making it a valuable compound in the field of medicinal chemistry. Its ability to target and inhibit the growth of harmful microorganisms and parasites contributes to the development of new treatments and preventive measures against infectious diseases.
Overall, 5-nitro-2-(trifluoroMethyl)pyridin-4-aMine is a multifaceted chemical compound with diverse applications across various industries, including pharmaceuticals, agrochemicals, dyes and pigments, and medicinal chemistry. Its unique structure and properties make it a valuable asset in the development of innovative products and solutions.

Upstream product

• 170886-13-2 4-hydroxy-2-trifluoromethylpyridine 
• 438554-45-1 4-chloro-5-nitro-2-(trifluoromethyl)pyridine 
• 438554-44-0 5-nitro-2-(trifluoromethyl)pyridin-4-ol 

Downstream Products

• 438564-37-5 6-(trifluoromethyl)pyridine-3,4-diamine 

Relevant academic research and scientific papers

FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF

The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method o

ANTIBIOTIC COMPOUNDS

The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS

The present invention provides compounds having the formula: (I) wherein A-B together represents one of the following structures; (II), (III), (IV) and n, R1, R2, R3, R4, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., RAF), and thus are useful, for example, for the treatment of RAF mediated diseases.

Benzimidazole and pyridylimidazole derivatives

This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.